261 related articles for article (PubMed ID: 31026023)
21. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
[TBL] [Abstract][Full Text] [Related]
22. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
Saller JJ; Haider M; Al-Diffalha S; Coppola D
Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
[TBL] [Abstract][Full Text] [Related]
23. Unsupervised and supervised learning with neural network for human transcriptome analysis and cancer diagnosis.
Yuan B; Yang D; Rothberg BEG; Chang H; Xu T
Sci Rep; 2020 Nov; 10(1):19106. PubMed ID: 33154423
[TBL] [Abstract][Full Text] [Related]
24. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
[TBL] [Abstract][Full Text] [Related]
25. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
Ordóñez NG
Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
[TBL] [Abstract][Full Text] [Related]
26. Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.
Penson A; Camacho N; Zheng Y; Varghese AM; Al-Ahmadie H; Razavi P; Chandarlapaty S; Vallejo CE; Vakiani E; Gilewski T; Rosenberg JE; Shady M; Tsui DWY; Reales DN; Abeshouse A; Syed A; Zehir A; Schultz N; Ladanyi M; Solit DB; Klimstra DS; Hyman DM; Taylor BS; Berger MF
JAMA Oncol; 2020 Jan; 6(1):84-91. PubMed ID: 31725847
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
Ordóñez NG
Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
[TBL] [Abstract][Full Text] [Related]
28. On the diagnosis of malignant pleural mesothelioma: a necropsy-based study of 171 cases (1997-2016).
Barbieri PG
Tumori; 2019 Aug; 105(4):361-362. PubMed ID: 30592233
[No Abstract] [Full Text] [Related]
29. DNA Methylation Markers for Pan-Cancer Prediction by Deep Learning.
Liu B; Liu Y; Pan X; Li M; Yang S; Li SC
Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31590287
[TBL] [Abstract][Full Text] [Related]
30. Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.
Xu Q; Chen J; Ni S; Tan C; Xu M; Dong L; Yuan L; Wang Q; Du X
Mod Pathol; 2016 Jun; 29(6):546-56. PubMed ID: 26990976
[TBL] [Abstract][Full Text] [Related]
31. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
Naso JR; Tsuji S; Churg A
Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
[TBL] [Abstract][Full Text] [Related]
32. CancerSiamese: one-shot learning for predicting primary and metastatic tumor types unseen during model training.
Mostavi M; Chiu YC; Chen Y; Huang Y
BMC Bioinformatics; 2021 May; 22(1):244. PubMed ID: 33980137
[TBL] [Abstract][Full Text] [Related]
33. Deep learning-based classification of mesothelioma improves prediction of patient outcome.
Courtiol P; Maussion C; Moarii M; Pronier E; Pilcer S; Sefta M; Manceron P; Toldo S; Zaslavskiy M; Le Stang N; Girard N; Elemento O; Nicholson AG; Blay JY; Galateau-Sallé F; Wainrib G; Clozel T
Nat Med; 2019 Oct; 25(10):1519-1525. PubMed ID: 31591589
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
Chirieac LR; Hung YP; Foo WC; Hofer MD; VanderLaan PA; Richards WG; Sugarbaker DJ; Bueno R
Cancer; 2019 Dec; 125(23):4164-4171. PubMed ID: 31390057
[TBL] [Abstract][Full Text] [Related]
35. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
37. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
[TBL] [Abstract][Full Text] [Related]
38. A platform-independent AI tumor lineage and site (ATLAS) classifier.
Rydzewski NR; Shi Y; Li C; Chrostek MR; Bakhtiar H; Helzer KT; Bootsma ML; Berg TJ; Harari PM; Floberg JM; Blitzer GC; Kosoff D; Taylor AK; Sharifi MN; Yu M; Lang JM; Patel KR; Citrin DE; Sundling KE; Zhao SG
Commun Biol; 2024 Mar; 7(1):314. PubMed ID: 38480799
[TBL] [Abstract][Full Text] [Related]
39. Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma.
Nakashima Y; Inamura K; Ninomiya H; Okumura S; Mun M; Kirimura S; Kobayashi M; Okubo K; Ishikawa Y
Lung Cancer; 2020 Oct; 148():20-27. PubMed ID: 32777673
[TBL] [Abstract][Full Text] [Related]
40. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
Berg KB; Churg A
Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
